- When considering interventions, ask: what is the risk of harm? If you do X what is the probability of benefit? What is the opportunity cost?
- The benefit of Continuous Glucose Monitoring (CGM) for people without diabetes is really is the insight it provides and the behavior change it can spark
- The value of the first 90 days with CGM is mostly insight and raising awareness without changing behavior – then it flips
In this special episode of The Drive, Peter Attia sits down with Head of Research at Attia Medical, PC Bob Kaplan (@bobkaplan) to discuss continuous glucose monitors, getting the most from zone 2 training, and foundational framework when considering interventions. Note, this is only a preview. The full episode is only available to subscribers.
Host: Peter Attia (@PeterAttiaMD)
Framework For Interventions
- Ask: what is the risk of harm? If you do X what is the probability of benefit? What is the opportunity cost?
- Phase 1 studies assess harm and rarely anything else because the sample size is small
- Phase 2 studies assess the efficacy
- Phase 3 trials double down on efficacy and opportunity cost
- The easiest interventions to do are pharmaceutical
Continuous Glucose Monitoring (CGM)
- We don’t have enough Randomized Controlled Trial (RCT) data to say CGM use is beneficial in people who are not diabetic
- Cons of CGM use: low risk of harm but can induce anxiety in some (e.g., people with eating disorders)
- Pros of CGM use: teaches you about carbohydrate tolerance, provides an opportunity for real-time changes
- Opportunity cost: they are expensive if you are not diabetic
- You can gain a lot of insight using them intermittently
First 90 days with CGM: 90% insight without behavior change, 10% behavior change – then it flips